RxDoctor Payments Data

Tsung Wong, MD

Family Medicine · Livermore, CANPI 1073513156

Payments from drug & device makers

$11,938in general payments, 2019–2025

Across 492 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Novo Nordisk$963
  • Boehringer Ingelheim$883
  • plus $5K from 35 others

What the payments were for

  • Travel & lodging$180%
  • Food & beverage$11,73498%
  • Education$1872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,938 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$236,519
Medicare patients
456
Services billed
2,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide98$172,454
Trelegy ElliptaFluticasone/Umeclidin/Vilanter147$118,346
EliquisApixaban128$117,329
JardianceEmpagliflozin28$45,097
FarxigaDapagliflozin Propanediol37$38,918
XareltoRivaroxaban43$33,274
VascepaIcosapent Ethyl49$27,182
MyrbetriqMirabegron44$26,454
ProliaDenosumab15$25,797
JanuviaSitagliptin Phosphate15$22,531
Breo ElliptaFluticasone/Vilanterol21$13,162
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$11,792
Icosapent Ethyl27$7,302
Spiriva RespimatTiotropium Bromide12$7,083
Levothyroxine Sodium424$6,987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$963$172,45498 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,674$143,300186 claims
PfizerEliquis$1,060$117,329128 claims
Boehringer IngelheimJardiance, Spiriva Respimat$883$52,18140 claims
AstraZenecaFarxiga$1,351$38,91837 claims
Johnson & JohnsonXarelto$99$33,27443 claims
AmgenProlia$101$25,79715 claims
MerckJanuvia$204$22,53115 claims
AbbVieCreon, Synthroid, Alphagan P$1,413$12,12861 claims
Lilly USA, LLCOlanzapine$322$2,11121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Livermore

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →